RFP, CGN and CGA Opportunities

The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at

Bristol-Myers Squibb

Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.

  • Cardiovascular
  • Immunoscience
  • Oncology
  • Virology
  • Genetically Defined / Rare Diseases

View Request for Proposals / for Education


Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a “healthcare Improvement” initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.

Therapeutic area(s) of interest:

  • Non-Malignant Blood Disorders

View Request for Proposal


Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest. 

Therapeutic areas of interest:

  • Opioid Use Disorder
  • Schizophrenia

To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis:

Insmed Incorporated

Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at Grant submissions should align to the specifications in the downloadable CGA.

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Education Activities associated with 2020 CHEST and IDWeek and other Medical Society Conferences

Submission Deadline: December 1, 2019

Download Call for Grants  

Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities. 

On March 2, 2018, CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP). 

For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on

Novo Nordisk Inc.

Novo Nordisk is committed to supporting independent medical education programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize patient or self care in the following therapeutic areas of interest:

  • Diabetes
  • Obesity

Please visit to apply for educational grants and access the IME Funding Document that provides information about educational priorities and available funding as well as current Request for Proposals (RFPs)/Call for Concept Proposals (CCPs) within these therapeutic areas.

Pfizer Independent Grants for Learning & Change (IGLC)

The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States. 

To view open RFPs and complete details, please visit this webpage.

Shionogi Inc.

Shionogi accepts funding requests within the following therapeutic areas of interest.

  • Gram-negative multidrug-resistant infectious disease (ID)
  • Thrombocytopenia associated with chronic liver disease (CLD)
  • Opioid-induced Constipation (OIC)

The call for grants (CFG) opportunities will change on a quarterly basis.  Please consult our website to identify current opportunities.

TRC Healthcare

TRC Healthcare (TRC), the creators of Pharmacist’s Letter, is committed to helping clinicians and healthcare professionals make safe, effective, and efficient medication decisions.  In support of this mission, TRC is currently accepting submissions in response to the following Requests for Proposals (RFPs).



Proposals may be submitted by individuals or groups and are due December 13, 2019.  Please see the individual RFPs for more details.


To learn more about TRC, please visit

UCB, Inc.

UCB, Inc., is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

6CB, Inc Medical Educational Grants, Medical Affairs, Request for Proposal (RFP): Psoriasis Educational Article

Click here to review the RFP. For complete details, please visit our website.

Proposal Deadline:  9/24/19

Anticipated Proposal Notification Date:  10/25/19